Digitised M-mode echocardiography was used to study the changes in left ventricular diastolic function over a 3-year period in 11 patients with hypertrophic cardiomyopathy an 14 normals. Compared to normal, in hypertrophic cardiomyopathy, isovolumic relaxation was prolonged (P less than 0.001) and mitral valve opening delayed relative to minimum dimension (P less than 0.001). There was a wide range of values for the peak rates of dimension increase and wall thinning, and although the means were normal, 6 and 8 patients respectively were outside the normal range. There were no significant mean changes in function during the 3.4 +/- 0.3 years of follow-up, but, in 3 patients, marked alterations in relaxation were observed. They showed a gross reduction in the delay in mitral valve opening (125 to 55 125 to 35 and 110 to 75 msec). There was little overall change in isovolumic relaxation in two, but in one patient it reduced from 95 to 50 msec. In most patients with hypertrophic cardiomyopathy, relaxation and diastolic function appear to remain stable over a period of 3 years, and none had an apparent deterioration. Some patients may have an apparently spontaneous "improvement" in function similar in extent to that described due to the therapeutic action of calcium antagonists.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0167-5273(85)90217-7DOI Listing

Publication Analysis

Top Keywords

hypertrophic cardiomyopathy
16
diastolic function
12
changes left
8
left ventricular
8
ventricular diastolic
8
patients hypertrophic
8
isovolumic relaxation
8
mitral valve
8
valve opening
8
function
5

Similar Publications

Introduction: Hypertrophic cardiomyopathy (HCM) is a common genetic heart disorder. It is characterized by left ventricular hypertrophy and impaired cardiac function, with forms categorized into obstructive (oHCM) and nonobstructive (nHCM). Traditional treatments address symptoms but not the underlying disease mechanism, highlighting the need for novel therapies.

View Article and Find Full Text PDF

Study Objective: Hypertrophic cardiomyopathy (HCM) is the most common genetic myocardial disorder increasingly characterized by concomitant metabolic syndrome. Cardiac rehabilitation (CR) has been shown to improve metabolic parameters in populations with heart failure and myocardial infarction. However, there is a paucity of data on the impact of CR in the HCM population with metabolic syndrome.

View Article and Find Full Text PDF

The year 2024 has seen significant progress in the management of heart failure. New treatments have demonstrated their efficacy, particularly for heart failure with preserved ejection fraction, cardiac amyloidosis, and hypertrophic cardiomyopathy. Advances in imaging, such as MRI and PET-CT, highlight the growing integration of innovative technologies and artificial intelligence in cardiology for diagnosing complex cardiovascular diseases.

View Article and Find Full Text PDF

Cardiac MRI Evaluation of Heart Failure and Cardiomyopathies.

R I Med J (2013)

February 2025

Brown University Health Cardiovascular Institute; Rhode Island, the Miriam and Newport Hospitals; Warren Alpert Medical School, Brown University.

Cardiac magnetic resonance imaging (CMR) is an exciting noninvasive imaging modality with increasing utilization in the field of cardiovascular medicine. In conjunction with echocardiogram, computed tomography, and invasive therapies, CMR has provided exceptional capability to further evaluate complex clinical cardiac conditions. CMR provides both anatomical and physiological information of a variety of tissue types, without the need for ionizing radiation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!